EMA Authorised: Zonisamide Viatris (previously Zonisamide Mylan) (zonisamide) — Viatris Limited

View source ↗

Summary

EMA authorised zonisamide for epilepsy under the Viatris Limited marketing authorisation. The product was previously marketed as Zonisamide Mylan.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epilepsy

Drugs mentioned

• Zonisamide Viatris (zonisamide)

Snippet

Status: Authorised. Therapeutic area: Epilepsy. MAH: Viatris Limited. Decision date: 21/10/2025